"The drug MIR-19 ... is completing the second phase of clinical trials," Skvortsova said in an interview with the Russia 24 TV channel as part of the Army-2021 forum.
It is noted that in September of this year, the agency plans to submit a report on the drug to the Russian Ministry of Health, after which the issue of registration of the drug will be decided.
"The drug is intended for the prevention or treatment of coronavirus through inhalation or intranasal administration," added Skvortsova.
According to her, the drug prevents the most severe forms of coronavirus infection.
In July, FMBA spoke about the effectiveness of the drug for the coronavirus "MIR-19".